Trial reportMedical oncology (Northwood, London, England)2017
Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.
Trial report in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications.Current opinion in urology · 2019Pooled it
- Pooled it
- Enhanced detection of bladder cancer using combined circulating tumor cells, urine-derived epithelial cells, and molecular biomarkers.Journal of cancer research and clinical oncology · 2026Article
- Review
- Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.Translational cancer research · 2024Review
- The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from Bladder Cancer: A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.Journal of translational medicine · 2023Article
- Bladder metastasis from type 2 papillary renal cell carcinoma: A case report.Oncology letters · 2023Article
- UroVysionCancers · 2022Review
- Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends.Cancers · 2022Review
- Fluorescence in situ hybridization (FISH) to predict the efficacy of Bacillus Calmette-Guérin perfusion in bladder cancer.Translational cancer research · 2022Article
- The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.Vaccine · 2021Review
- Follow-up in non-muscle invasive bladder cancer: facts and future.World journal of urology · 2021Review
- Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise.Cancers · 2020Review
- Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.The Journal of pathology · 2019Review
- Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics.International urology and nephrology · 2019Review
- Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers.Translational andrology and urology · 2018Article
- Unmasking molecular profiles of bladder cancer.Investigative and clinical urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette-Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.